NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
Novocure stock last closed at $22.48, up 3.55% from the previous day, and has increased 43.92% in one year. It has overperformed other stocks in the Medical Devices industry by 0.52 percentage points. Novocure stock is currently +92.14% from its 52-week low of $11.70, and -34.13% from its 52-week high of $34.13.
As of Feb 14, 2025, there are 108.2M NVCR shares outstanding. The market cap of NVCR is $2.43B. In the last 24 hours, 740,147 NVCR shares were traded.
You need an online brokerage account to access the NASDAQ market and buy NVCR stock.
Based on our experience, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your stock purchase by signing up for an account with eToro today.
Open eToro AccountNow that you've picked your brokerage, the next step is to fill out some personal info so you are able to invest in NVCR stock today.
Now that you have finished signing up on one of the best stock apps, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing funds into your new investment account.
Once you have selected the best place to buy Novocure stock, it's critical to evaluate their stock prior to buying, so you actually comprehend the risk and upside.
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can see all of the due diligence checks on NVCR's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NVCR's intrinsic value.
Using relative valuations ratios:
You can access additional valuation research on NVCR's stock here.
Out of 3 Equities analysts who give recommendations on NVCR, the consensus analyst rating on Novocure is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Novocure stock forecast page.
Last year, NVCR revenue was $577.74M. During the past five year, NVCR's revenue has increased by 12.42% per year. This was faster than the Medical Devices industry average of 9.98%.
Learn more about NVCR's earnings and revenue performance here.
Over the past year, executives and large shareholders at NVCR have bought more shares than they have sold.
Mukund Paravasthu, Chief Operating Officer of NVCR, was the latest NVCR insider to sell. They sold $57,905.28 worth of NVCR shares on Jan 11, 2025.
Dig into more about who owns NVCR stock here.
No, Novocure doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
You have two main order types:
Click the Open Trade button and eToro will place your order.
If you want additional help investing in stocks on eToro, watch the helpful video below:
Now that you own some NVCR shares, you'll want to stay up-to-date on your new company.
Add NVCR to a watchlist to keep tabs on your NVCR stock.
To reiterate, here are the 6 steps to buy Novocure stock:
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Novocure, hit the button below to create your watchlist.